Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults.
Saved in:
| Title: | Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults. |
|---|---|
| Authors: | Mayer L; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. l.mayer@uke.de.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. l.mayer@uke.de.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany. l.mayer@uke.de., Fathi A; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.; First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Weichel HM; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Raadsen MP; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands., Dahlke C; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Mykytyn A; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands., Rodon J; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Gerresheim GK; Institute of Virology, Philipps University Marburg, Marburg, Germany.; German Center for Infection Research, partner site Gießen-Marburg-Langen, Marburg, Germany., Te Marvelde MR; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands., Weskamm LM; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Grewe I; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Schlesner C; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Lütgehetmann M; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.; Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Drosten C; Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.; German Center for Infection Research, associated partner Charité, Berlin, Germany., Becker S; Institute of Virology, Philipps University Marburg, Marburg, Germany.; German Center for Infection Research, partner site Gießen-Marburg-Langen, Marburg, Germany., Haagmans BL; Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands., Hardtke S; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany., Addo MM; Institute for Infection Research and Vaccine Development (IIRVD), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. m.addo@uke.de.; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. m.addo@uke.de.; German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany. m.addo@uke.de. |
| Source: | Nature communications [Nat Commun] 2026 Jan 09; Vol. 17 (1), pp. 480. Date of Electronic Publication: 2026 Jan 09. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
